Table 1.

Baseline demographic and clinical characteristics in study sample.

N	929
Gender (% female)	75
Age (years, mean ± SD)	41 ± 10.5
Disease duration (years, mean ± SD)	7.9 ± 8.1
Race (% white)	95
Follow-up time (months, mean ± SD)	44.7 ± 29.4
EDSS (mean ± SD)	1.22 ± 1.08
Pyramidal scale (mean ± SD)	0.61 ± 0.82
Cerebellar scale (mean ± SD)	0.28 ± 0.66
Brainstem scale (mean ± SD)	0.15 ± 0.43
Sensory scale (mean ± SD)	0.53 ± 0.77
Bowel bladder scale (mean ± SD)	0.27 ± 0.56
Mental scale (mean ± SD)	0.17 ± 0.49
Visual scale (mean ± SD)	0.22 ± 0.66
Treatment (% IFN, % GA, % other, % untreated)	29.7, 30.9, 7.2, 32.2

EDSS: expanded disability status scale, IFN: all forms of interferon-β, GA: glatiramer acetate, other: natalizumab, rituximab, cyclophosphamide, daclizumab, mycophenolate mofetil, mitoxantrone, or combination treatment.